Compare IQIYI Inc - ADR (IQ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Zimmer Biomet Holdings Inc — how do they compare? IQIYI Inc - ADR trades at $1.35 (market cap $1.30B), while Zimmer Biomet Holdings Inc trades at $95.69 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 14.3× IQIYI Inc - ADR's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals.
| IQ | ZBH | |
|---|---|---|
Market Cap | $1.30B | $18.55B |
Sector | Media | Health |
52-Week High | $2.79 | $107.71 |
52-Week Low | $0.96 | $79.58 |
Enterprise Value | $2.88B | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQ (iQIYI) trades at $1.33, down 2.21% today, with a bullish technical signal from moving averages but overbought RSI readings. Revenue declined to $27.29B in 2025, with a net loss of $206.31M, though the company beat EPS expectations in two recent quarters. Recent news highlights AI platform growth and executive changes, while analyst sentiment is mixed with 50% buy ratings.
The outlook hinges on AI-driven content innovation and cost management to reverse profitability challenges, but risks include intense competition and regulatory pressures in China. Upside potential exists if execution improves, yet near-term volatility may persist amid earnings uncertainty and macroeconomic headwinds.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
